The genetic data services provider raised the cash from GSK as part of a collaboration deal, taking its total funding past $790m.
Pharmaceutical firm GlaxoSmithKline (GSK) has invested $300m in US-based DNA services provider 23andme as part of a four-year collaboration agreed by the companies yesterday.
Founded in 2006, 23andme runs a service enabling users to send their genetic data to be tested in order to get information on their ancestry or risk of diseases such as Alzheimer’s or Parkinson’s disease.
Customers provide a saliva sample at home using the company’s DNA collection kit and the samples are processed in between six…
